drugset / Trial / NCT06014853

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects

NCT06014853

Phase 1 Completed 48 enrolled Bukwang Pharmaceutical Dyna Therapeutics · collab
RandomizedCrossoverOpen-labelTreatment

Summary

Study Design : A randomized, open-label, four-sequence, four-period, crossover, single dosing, phase 1 study

Timeline

Start
2023-08-10
Primary completion
2023-10-28
Completion
2023-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiraterone acetate Small molecule 1000 mg Oral
Subject SOL-804-F Unknown 181.5 mg Oral
Subject SOL-804-F Unknown 242 mg Oral
Subject SOL-804-F Unknown 302.5 mg Oral

Indications